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Synthesis of Novel Heteroleptic Delocalised Cationic Pyrazole Gold 
Complexes as Potent HepG2 Cytotoxic Agents  
 Fatai Afolabi,a Wided Souissi,b Guillaume Rivière, a Clément Lemaitre, a S. Mark Roe,a Neil 
Crickmoreb* and Eddy M. E. Viseuxa* 
 
A new series of cationic gold(I) pyrazole complexes were prepared 
in excellent yields as their perchlorate salts. Results of cell viability 
assays show that these novel complexes have good cytotoxic 
properties against the human HepG2 cancer cell line. These 
complexes showed promising anti-cancer activities and to our 
knowledge, pyrazoles have never been tested against this cell line. 
The regioselectivity of the complexation is also discussed in regards 
to the substitution pattern of the pyrazoles. 
Introduction 
Significant efforts have been made to advance the field of new 
transition metal-based drugs, with significant breakthroughs in 
chemotherapy and other diseases.1,2,3 Many organometallic 
drugs employ the ability of a metal to lose one or more 
electrons to form a soluble cationic complex in biological fluids 
and exacerbate their binding affinity as a cation with biological 
electron donors such as DNA and proteins.4 Their targets can 
include carriers of vital molecules to body tissues or the 
provision of structural frameworks to the body. Metals are also 
embedded into catalytic proteins and facilitate various chemical 
reactions essential for life.4 The synthesis of organometallic 
complexes for biological reasons attracts considerable interest 
due to their wide-ranging applications, such as amino acid 
synthesis.5 Over the past two decades, interest has increased in 
the organogold complexes for their high medicinal activities. 
Their structural design with simple and potent ligands are key 
aspects of medicinal inorganic chemistry with uses targeting 
varied afflictions such as asthma, malaria, rheumatoid arthritis, 
HIV6  and cancer.7,8 Furthermore, gold complexes are an 
excellent prototype for the rational design and development of 
novel and effective anti-cancer agents.9 The activity of gold(I) 
complexes stems from their ability to penetrate the 
mitochondria and subsequently bind to the selenocysteine 
residue in thioredoxin reductase (TrxR).10  TrxR is an enzyme 
usually over-expressed in tumour cells and involved in the 
growth and apoptosis of the cell. This overexpression hinders 
the apoptotic pathways.7 The specificity of gold for 
mitochondria in cancerous cells was shown to arise from their 
hyperpolarisation, resulting in increased drug uptake compared 
to healthy cells, as we previously demonstrated.3 11  
We investigated the design flexibility provided by anti-cancer  
agents based on gold(I) and found that gold with an amide 
linkage exhibit substantial activity against mammalian breast 
cancer cells.12 This discovery on the nature of the linkage to gold 
to retain substantial anti-cancer activity regardless of the 
structure of the ligands is crucial to outsmart cancer resistance 
and improve potency. Ligand design has since been focused on 
features that are complementing the gold apoptotic pathways 
against cancerous cells. We decided to investigate pyrazoles 
because of their high medicinal value.13 They are important 
building blocks used in pharmaceutical and agrochemical 
industries.14,15,16 Pyrazole is a special class of heterocyclic 
compound that can not only coordinate to enzymes (through 
van der Waals interactions) but also to metals, making them 
useful templates for the design of novel drugs.13,17 Their motif 
is also present in many biologically active compounds.18 The 
structure/activity relationship (SAR) of pyrazoles alone has been 
extensively investigated and they were found to bind to a 
variety of receptors, enhancing the activity of many anti-
angiogenesis agents.19  Pyrazoles have also shown great pro-
apoptotic potential against lung cancer cell lines20 as well as 
excellent cytotoxicity against cells carrying the p53 cancer 
mutation Y220C.21 Pyrazolates and imidazolates substituted 
with deactivating groups were used to synthesise neutral 
azolate gold(I) phosphane complexes and were found to act as 
anti-cancer  agents.22 The choice of the substitution pattern was 
based on previous observations whereby substitution R3 at the 
4-position (scheme 1) seemed to stabilise binding to p53-Y220C 
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through London interactions in a lipophilic pocket.21 
Substitution at the N2-position and N1- positions A closer look 
at the X-ray diffraction of the protein shows further possible 
interactions, notably Debye and Keesom dipolar interactions 
with the carbonyl at P153 and P152. We decided to include a 
range of substitutive functional groups (pyridine, bromo-
phenyl, nitrile and bromine) to verify any impacts of such 
interactions on the activity of our complexes.  The inhibitory 
properties of neutral gold(I)  triphenylphosphine complexes on 
E. coli dihydrofolate reductase was found to be toxic against 
different human cancer cell lines.23 
In our search for dual action orthogonal drug and based on our 
previous observations of the reactivity of gold amide complexes 
on cancer cells,12 we decided to investigate a different class of 
amide ligands that is known to be active against cancer cells, yet 
with a different pathway to that of gold(I) alone, to further the 
applicability of anticancer drug candidates based on a gold-
nitrogen bond.  We investigated in this paper the role of 
delocalised cationic gold pyrazole complexes against the HepG2 
human liver cancer cell line. HepG2 is a cell line widely used as 
a model system for hepatocyte cancers. Hepatocellular 
carcinomas are notoriously difficult to treat due to the ease at 
which they develop resistance to most common 
chemotherapeutic drugs.24 
Results and Discussion 
Synthesis of the complexes 
We herein report on the complexation of pyrazole ligands 1-5 
to form an array of pyrazole gold(I) complexes 6-10 (Scheme 1, 
Table 1). 
 
Scheme 1. Regioselective synthesis of pyrazole 
triphenylphosphinegold(I) perchlorates 6-10. 
The synthesis of these complexes is commonly hampered by 
long reaction times (two  days and more)25 and so our 
procedure was optimised to give rapid, facile and reproducible 
results. The successful synthesis of the intermediary cationic 
triphenylphosphinegold perchlorate was systematically 
assessed by 31P NMR, and a single peak between 27 and 29 ppm, 
depending on the concentration, was observed. All complexes 
were characterised by 1H, 13C and 31P NMR and their positive-
ion ESI-MS displayed the [M]+ peaks in agreement with the 
calculated isotopic pattern. Minor partial disproportionation to 
homoleptic complexes and to [Au(PPh3)2]+ was observed for 
complex 6 (less than 0.1%) and for complex 9 (5%). 
Unfortunately, satisfactory crystals could not be grown for 
complex 6, so its structure could not be ascertained. However, 
based on our observation for complexes where R1 = H, it is 
highly probably that the regioselectivity should favour complex 
6a over 6b. The results are collated in table 1. 
   Table 1: Synthesis of gold(I) pyrazole complexes. 
Entry R1 R2 R3 Complex Yield 
1 H H Py 6 83% 
2 H H Br-Ph 7a 94% 
3 H Methyl Br-Ph 8a 88% 
4 C2H4OH H CN 9b 95% 
5 Methyl H Br 10b 87% 
X-Ray diffraction 
Suitable crystals for x-ray crystallography of complexes 7-10 
were obtained by slow evaporation of dichloromethane and n-
hexane in a [1:1] ratio although the crystals for complex 6 were 
too small for x-ray diffraction. The crystals were characterised 
by X-ray crystallography to confirm the atom connectivity and 
molecular geometry. The main results of the crystal structure 
determinations are reported in Table 2. Table 3 lists some 
selected bond lengths and angles of the four complexes.  
Table 2. Crystal Data for complexes 7a, 8a, 9b and 10b 
 7a 8a 9b 10b  
Empirical formula C28H25N3PBrA
u, ClO4 
C27H23N3P
BrAu, 
ClO4 
C24H23N4OP
Au, ClO4 
C22H21N3PBr
Au, ClO4, 
CH2Cl2 
Formula weight 810.80 796.78 710.85 819.64 
Temperature/K 100.0(1) 173.0(1) 173.0(1) 173.0(1) 
Crystal system Triclinic Orthorhom
bic 
Triclinic Monoclinic 
Space group P-1 Pbcn P-1 P21/c 
a/Å 12.7645(4) 18.9094(6) 13.2511(11) 13.8129(4) 
b/Å 15.6061(5) 16.3880(5) 14.8189(13) 6.9184(2) 
c/Å 16.4732(4) 17.9115(5) 15.7353(12) 29.6985(9) 
α/° 105.959(2) 90 66.312(8) 90 
β/° 93.268(2) 90 74.845(7) 103.268(3) 
γ/° 112.402(3) 90 66.970(8) 90 
Volume/Å3 2868.22(16) 5550.6(3) 2584.0(4) 2762.33(14) 
Z 4 8 4 4 
ρcalc/Mg/m-3 1.878 1.907 1.827 1.971 
μ/mm-1 12.982 13.404 12.601 15.222 
F(000) 1568.0 3072.0 1384.0 1576.0 
Crystal size/mm 0.14 x 0.12 x 
0.02 
0.22 x 0.12 
x 0.08 
0.32 x 0.10 x 
0.04 
0.36 x 0.08 x 
0.06 
Reflections 
collected 
31051 10573 15895 16828 
Independent 
reflections/R(int) 
10158/0.0544 5023/0.039
3 
9215/0.0310 5048/0.0394 
Data/restraints/para
meters 
10158/60/707 5023/331/3
43 
9215/8/671 5048/39/327 
Goodness-of-fita on 
F2 
1.093 1.057 1.022 1.151 
Final R indexes 
[I>2σ(I)] 
R1b=0.0612, 
wR2c= 0.1639 
R1b=0.075
5,    wR2c= 
0.2012 
R1b=0.0338, 
wR2c= 
0.0906 
R1b=0.0497, 
wR2c= 
0.1424 
Largest diff. 
peak/hole/e Å-3 
5.17/-2.72 2.10/-1.10 1.25/-1.83 3.26/-1.29 
a Goodness-of-fit = [Σ(w(Fo2 – Fc2)2]/(Nobsevns – Nparams)]1/2, based 
on all data. 
b R1 = Σ(|Fo| - |Fc|)/Σ(|Fo|, c wR2 = [Σ[w(Fo2 – Fc2)2]/Σ[w(Fo2)2]]1/2. 
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Table 3. Selected bond lengths (Å) and angles (°) for complexes 
7a, 8a, 9b and 10b 
 7a 8a 9b 10b 
Au – N1 2.048(7)  2.075(3), 
2.055(4) 
2.056(7) 
Au – N2 2.042(6) 2.068(10)   
Au – P 2.238(2), 
2.233(2) 
2.241(3) 2.234(1), 
2.223(1) 
2.234(2) 
N1 – N2 1.368(9), 
1.374(8) 
1.341(15) 1.368(5), 
1.374(5) 
1.367(11) 
N1 – C5 1.337(10), 
1.330(10) 
1.317(16) 1.325(6), 
1.333(6) 
1.317(12) 
N2 – C3 1.338(10), 
1.355(9) 
1.354(15) 1.351(6), 
1.343(6) 
1.357(12) 
C3 – C4 1.393(11), 
1.405(10) 
1.382(16) 1.402(6), 
1.407(6) 
1.398(13) 
C4 – C5 1.412(11), 
1.396(11) 
1.379(16) 1.384(6), 
1.383(6) 
1.395(13) 
C3 – N6  1.393(10), 
1.410(10) 
1.327(17) 1.342(6), 
1.337(6) 
1.340(13) 
C4 – C7 1.477(10), 
1.470(11) 
1.484(16) 1.419(6), 
1.418(6) 
 
C4 – Br7    1.859(9) 
P – C9 1.815(8), 
1.817(7) 
1.803(12) 1.812(4), 
1.814(4) 
1.812(9) 
P – C10 1.818(8), 
1.811(7) 
1.805(12) 1.813(5), 
1.801(5) 
1.816(9) 
P – C11 1.808(7), 
1.816(7) 
1.795(15) 1.819(4), 
1.805(4) 
1.813(9) 
     
N1 – Au – P 176.68(19)  176.01(11), 
176.98(11) 
175.3(2) 
N2 – Au – P 178.56(17) 175.3(3)   
Au – N1 – N2 123.3(5)  125.7(3), 
125.1(3) 
124.4(6) 
Au – N2 – N1 123.4(5) 119.9(8)   
Au – N1 – C5 131.1(5)  125.7(3), 
127.6(3) 
125.5(6) 
Au – N2 – C3 130.3(5) 133.0(9)   
Au – P – C9 116.4(3), 
111.3(2) 
109.8(4) 113.42(14), 
109.91(14) 
113.4(3) 
Au – P – C10 112.7(2), 
111.8(2) 
114.5(4) 111.98(14), 
113.82(16) 
112.1(3) 
Au – P – C11 109.3(2), 
112.8(2) 
113.1(4) 113.86(14), 
113.15(14) 
112.2(3) 
N1 – N2 – C3 111.6(6), 
105.6(6) 
106.5(10) 110.4(3), 
110.4(3) 
110.3(8) 
N2 – C3 – C4 107.5(7), 
110.1(6) 
109.3(10) 106.5(4), 
106.4(3) 
106.1(8) 
C3 – C4 – C5 104.6(7), 
104.9(6) 
104.9(10) 105.8(4), 
106.3(4) 
106.2(8) 
C4 – C5 – N1 110.7(7), 
108.2(6) 
108.8(11) 110.5(4), 
109.8(4) 
109.9(8) 
C5 – N1 – N2 105.5(6), 
111.1(6) 
110.5(10) 106.8(3), 
107.0(3) 
107.4(8) 
N2 – C3 – N6 120.8(7), 
121.2(6) 
120.7(12) 124.5(4), 
124.0(4) 
125.3(9) 
N6 – C3 – C4 131.6(7), 
128.7(7) 
129.9(12) 128.9(4), 
129.4(4) 
128.3(9) 
C3 – C4 – C7 129.2(7), 
128.2(7) 
126.2(10) 126.5(4), 
126.6(4) 
 
C7 – C4 – C5 126.2(7), 
126.9(7) 
128.8(11) 127.6(4), 
127.0(4) 
 
C3 – C4 – Br7    125.6(7) 
Br7 – C4 – C5    128.2(7) 
C4 – C5 – C8 129.6(7), 
131.3(7) 
   
C8 – C5 – N1 119.6(7), 
120.5(7) 
   
Figure 1 shows the structures in ORTEP format with the selected 
numbering scheme.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 1. ORTEP views of complexes 7a, 8a, 9b and 10b, showing 
the numbering scheme used.  
Selected crystalline specimens of the complexes 8a, 9b and 10b 
were mounted on Mitegen loops and centered on the 
 
Complex 7a 
 
Complex 8a 
 
Complex 9b 
 
Complex 10b 
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goniometer head of a Rigaku Oxford Diffraction Gemini E 
diffractometer equipped with an EOS CCD area detector, data 
collection was performed at 173K. Complex 7a was collected on 
a Rigaku Oxford Diffraction 007HFM/AFC11 diffractometer 
equipped with a Saturn 944+ CCD area detector at 100K. All 
complexes were collected with monochromated CuKα 
radiation, by means of ω-scans. The diffraction intensities were 
corrected with respect to Lorentz and polarization effects. 
Empirical multi-scan absorption corrections, using equivalent 
reflections, were also performed with the scaling algorithm 
SCALE3 ABSPACK. Raw data collection, data reduction and 
refinalisation were carried out with the CrysAlisPro software. All 
complexes were solved by means of the intrinsic phasing 
method in SHELXT2623and refined by full-matrix least squares 
methods based on Fo2 with SHELXL27in the framework of the 
OLEX228software. In the last cycles of refinement all non-
hydrogen atoms were refined anisotropically; hydrogen atoms 
were placed and refined as riding atoms with their isotropic 
displacement parameters set to 1.2 times the Ueq of the parent 
atom. The best crystal of complex 7a necessitated the collection 
on the Rigaku 007HFM due to its small size. In complex 8a, there 
is a small amount of disorder relating to the ligand binding 
through N2 or N1. The amount of disorder was too low to model 
satisfactorily, so this has been left unmodelled. The molecular 
structures of all complexes contained a two-coordinate Au 
centre with expected Au-P (2.2-2.4Å) and Au- N (2.0-2.2Å) 
distances and linear coordination irrespective of the state of 
molecularity in the crystal (Table  3).11 The Au-P were in very 
good agreement with 2.25 Å reported by Keter et al29 and 2.26 
Å results of Cambridge Structural Database (CSD).29 The 
perchlorate molecule was included in the lattice of the 
complexes 7-10 and CH2Cl2 was present only in the lattice of 
complex 10b. These display H-bonding to the NH2 and the 
endocyclic NH when R1=H. Ligand 1 has a pyridine at the fourth 
position, which provides another possible point of attachment 
compared to others. There is four possibilities for the point of 
attachment to gold (I). Therefore, four peaks were expected by 
31P NMR but only one peak at 30.0 ppm was observed indicating 
that there is only one possible linkage. Ligand 2 is a pyrazole 
with a bromophenyl at position 4 with three possible points of 
attachment but only one peak at 31.0 ppm was observed. X-ray 
crystallography also confirmed one linkage. The point of 
attachment was the nitrogen at the position one replacing the 
proton in that position but leaving a positive charge on the 
nitrogen ligand 3 has a similar structure to ligand 2 but with a 
methyl group at position three. Three points of attachment 
were also possible but the 31P NMR indicated a single 
attachment point to gold (I) by given only one peak at 31.50 
ppm. X-ray result also confirmed the single point of attachment 
but indicated that complex 8a is a regioisomer with a positive 
charge on the nitrogen in position 1.  Ligand 4 has a cyano group 
at position four and an ethyl alcohol at position two given 
different likely point of attachment. However, 31P NMR of the 
complex gave a single peak at 29.7 ppm indicating a single point 
of attachment to gold (I). X-ray diffraction indicated that 
complex 9b is a regioisomer with only one point of attachment 
to gold (I).  Ligand 5 has a bromo substituent at position 4 and a 
methyl group at position one. 31P NMR indicated only one point 
of attachment with a single peak at 30.0 ppm and attested to by 
the x-ray diffraction study. The point of attachment was at 
position 2. Complex 10b is non regioisomeric. 
Cell viability assays 
The biological activity of the complexes were assessed after 
dilution in DMSO/H2O (10% v/v) and addition to HepG2 cells. 
Assays were performed in 96-well plates using the Promega 
CellTiter-Blue assay as an endpoint method with a 2-hour 
incubation with the assay reagent. This assay measures cell 
viability and is based upon the ability of living cells to convert a 
redox dye (resazurin) into a fluorescent product (resorufin). 
Each well received 90 μL of cell suspension at a density of 22,500 
cells per well and was cultured overnight (at 37 °C/5% CO2 
humidified air) before 10 μL of the test sample was added. The 
experiments were set up in triplicate. The mock control wells 
received 90 μL of cell suspension and 10 μL of the appropriate 
buffer (DMSO/H2O). Wells that contained just 100 μL of cell 
culture medium served as background fluorescence controls. 
Fluorescent readings were taken using the GloMax-Multi 
Detection System (Promega).  
The five complexes shown in Table 1 all indicated that they 
possessed reasonable activity against this cell line in a 
preliminary screen (data not shown). To confirm this activity 
various doses were then tested alongside their respective un-
complexed ligands. Figure 2 shows that even at the lowest dose 
tested (20 μM) all of the complexes showed high activity. In 
contrast the free ligands showed no significant activity at the 
same concentrations. Due to the high level of activity observed, 
further dilutions were made and tested (Figure 3). These data 
indicate that complexes 7a, 8a, 9b and 10a remain highly toxic 
at 2 μM while 6 is significantly less toxic at this concentration. 
IC50 values were calculated as 1.75 μM (6), 0.19 μM (7b), 0.31 
μM (8b), 0.13 μM (9a) and 0.23 μM (10a). 
 
Figure 2. Toxicity data for the gold complexes (6-10 right hand 
scale) and their associated ligands (1-5 left hand scale) against 
HepG2 cells. Five doses of each compound were tested, 
background fluorescence was subtracted from each reading and 
the resulting values are shown relative to a buffer-only control 
(100% viability). Controls performed under full assay conditions 
confirmed that none of the compounds, or the separate ligands, 
interfered with the readings when tested at a concentration of 
18 μM in the absence of cells. Error bars represent one standard 
error of the mean (SEM). 
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Figure 3. Dose response assay of gold complexes against HepG2 
cells. Five doses of each complex were tested, background 
fluorescence was subtracted from each reading and the 
resulting values are shown relative to a buffer-only control 
(100% cell viability). Error bars represent one standard error of 
the mean (SEM).  
Conclusions 
Five new monocationic pyrazolium gold complexes 6-10 have 
been prepared in excellent yields and the substitution pattern 
did not seem to have a notable effect on their activity against 
the cancer cell line described herein. This flexibility in the design 
is desirable when fine tuning structural motifs for druggable 
applications. The regioselectivity of the complexation was 
found to be dependent on the substitution pattern on the 
endocyclic nitrogen N1, favouring the complexation of the 
nitrogen proximal to the 5-amino group when R1 = H. All 
compounds are highly active against HepG2 cancer cells and 
display activity in the submicromolar range comparable to our 
previous work on gold complexes and breast cancer cell lines.3 
Futhermore their efficacy compares well to other 
chemotherapeutic drugs on this cell line30 including Doxorubicin 
(IC50 1.1 μM) and Cisplatin (IC50 15.9 μM) Hepatocellular 
carcinomas readily acquire resistance to chemotherapeutic 
drugs – usually through the expression of a multidrug efflux 
pump. It is unknown whether these mechanisms would prevent 
the action of our gold amides or whether they have potential in 
treating resistant cells. This work therefore provides strategic 
tools to investigate such avenues of research. 
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